Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bioage LabsBIOA -1.78%12 PB Ratio is 1.28 as of Aug. 12, 2026, which is 2% above its 10-year median of 1.26. GuruFocus rates BIOA with a GF Score™ of 12/100. The stock has 3 warning signs investors should review. Among 920 Drug Manufacturers companies, Bioage Labs ranks better than 67.93% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-08-12), Bioage Labs's share price is $10.485. Bioage Labs's Book Value per Share for the quarter that ended in Jun. 2026 was $8.19. Hence, Bioage Labs's PB Ratio of today is 1.28.
The historical rank and industry rank for Bioage Labs's PB Ratio or its related term are showing as below:
BIOA'
s PB Ratio Range Over the Past 10 Years
Min: 0.38 Med: 1.26 Max: 3.06
Current: 1.25
During the past 4 years, Bioage Labs's highest PB Ratio was 3.06. The lowest was 0.38. And the median was 1.26.
BIOA's PB Ratio is ranked better than 67.93% of 920
companies
in the Drug Manufacturers industry
Industry Median: 1.98
vs BIOA: 1.25
During the past 12 months, Bioage Labs's average Book Value Per Share Growth Rate was 1.70% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Bioage Labs PB Ratio Related Terms
Bioage Labs PB Ratio Historical Data
* Premium members only.
The historical data trend for Bioage Labs's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bioage Labs's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioage Labs PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bioage Labs's PB Ratio distribution charts can be found below:
* The bar in red indicates where Bioage Labs's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Bioage Labs's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Bioage Labs (BIOA) has a PB Ratio of 1.28 as of Aug. 12, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Bioage Labs and its competitors. This is near median its historical median of 1.26. Over the past decade, Bioage Labs' PB Ratio has ranged from 0.38 to 3.06. According to the industry distribution chart, Bioage Labs ranks #295 out of 920 companies in the Drug Manufacturers industry, placing it in the top 32.1%.
Is Bioage Labs' PB Ratio too high?
Bioage Labs' current PB Ratio of 1.28 is near median its 10-year median of 1.26. Over the past 10 years, this metric has ranged from a low of 0.38 to a high of 3.06. The Drug Manufacturers industry median PB Ratio is 1.98. Bioage Labs' value of 1.28 is 35.4% below this industry median. Based on the distribution chart, Bioage Labs ranks #295 out of 920 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Bioage Labs has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Bioage Labs' PB Ratio compare to PCRX and ALVO?
According to the Drug Manufacturers industry distribution chart, Bioage Labs ranks #295 out of 920 companies for PB Ratio. This puts Bioage Labs in the upper half of its industry. The industry median PB Ratio is 1.98. Bioage Labs' value of 1.28 is 35.4% below this benchmark. Historically, Bioage Labs' own PB Ratio has ranged from 0.38 to 3.06 over the past decade. While the company's 10-year median is 1.26 vs. the industry median of 1.98, Bioage Labs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.98, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bioage Labs's current PB Ratio of 1.28 is 35.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Bioage Labs and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioage Labs's current PB Ratio is 1.28, which is near median its own 10-year median of 1.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioage Labs stock overvalued right now?
Bioage Labs (BIOA) has a current PB Ratio of 1.28. The current PB Ratio is 1.28, which is near median its 10-year median of 1.26 and 35.4% below the Drug Manufacturers industry median of 1.98. Bioage Labs' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Bioage Labs (BIOA), the current PB Ratio is 1.28 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.
12GF Score
Get the complete analysis for BIOA
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BIOA has been successfully added to your 
